Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

April 30, 2003

Conditions
Ovarian Cancer
Interventions
DRUG

rubitecan

Trial Locations (13)

6500

Ospedale San Giovanni, Bellinzona

13385

CHU de la Timone, Marseille

21079

Centre de Lutte Contre le Cancer, Georges-Francois Leclerc, Dijon

28041

Hospital Universitario 12 de Octubre, Madrid

35042

Centre Eugene Marquis, Rennes

35128

Azienda Ospedaliera di Padova, Padova (Padua)

44805

CRLCC Nantes - Atlantique, Nantes-Saint Herblain

49100

Rabin Medical Center - Beilinson Campus, Petah Tikva

63011

Centre Jean Perrin, Clermont-Ferrand

B-1000

Institut Jules Bordet, Brussels

Ch-1272

Clinique De Genolier, Genolier

NE4 6BE

Newcastle General Hospital, Newcastle upon Tyne

EH4 2XU

Western General Hospital, Edinburgh

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00006230 - Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer | Biotech Hunter | Biotech Hunter